- AC Immune (NASDAQ:ACIU) announces that Genentech, a member of the Roche Group (OTCQX:RHHBY), has initiated a substudy in the ongoing Phase 2 Alzheimer’s Prevention Initiative (API) trial of AC Immune’s, crenezumab.
- The substudy, which measures Tau burden, aims to increase the understanding of disease progression in the preclinical stage of autosomal dominantly inherited Alzheimer’s disease (AD).
- The substudy will evaluate the effect of crenezumab, an anti-Abeta antibody, on the longitudinal Tau burden, to slow or prevent the decline of cognitive and functional abilities in people at risk of developing familial AD.